WINT - Windtree Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

WINT

WINDTREE THERAPEUTICS, INC.

OTC

$0.00

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$3.37 K

52w High$0.19

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume70.00K

Shares Out.33.71M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jed A. Latkin

COMPENSATION 2026

Salary$0

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$0

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 7, 1995

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateAug 31, 2026

DayMonday

Rev. Est.—

AUG

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-02-21	Reverse	1:50
2024-04-22	Reverse	1:18
2023-02-24	Reverse	1:50
2020-04-29	Reverse	1:3
2017-12-22	Reverse	1:20
2016-01-22	Reverse	1:14
2010-12-28	Reverse	1:15
1997-12-01	Reverse	1:3

PRICE

$0.00 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Windtree Therapeutics, Inc.

https://windtreetx.com ↗

Windtree Therapeutics, Inc. is a clinical-stage biopharma developing therapies for acute cardiovascular and pulmonary diseases, with programs in Phase II trials and collaborations worldwide.

INDUSTRY

Biotechnology

A SERVICE WINDTREE THERAPEUTICS, INC. IS KNOWN FOR

Pharmaceutical Sourcing and Manufacturing Partnership

After selling its cardiovascular pipeline in 2025, Windtree Therapeutics now focuses on revenue-generating sourcing and manufacturing partnerships, including its March 2025 deal with Evofem Biosciences for PHEXXI®.